Literature DB >> 2910634

Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.

G A Verpooten1, R A Giuliano, L Verbist, G Eestermans, M E De Broe.   

Abstract

The pathogenesis of aminoglycoside nephrotoxicity is intimately related to the extent of drug accumulated in the renal cortex. In the framework of searching for preventive measures of aminoglycoside-induced nephrotoxicity, we investigated the influence of dosage regimen on the renal cortical accumulation of gentamicin and netilmicin in humans. Patients with a tumor partly involving one kidney, with normal renal function, and scheduled for nephrectomy received one dose of either gentamicin (4.5 mg/kg) or netilmicin (5 mg/kg) as a single short-term infusion or as 24-hour continuous infusion. Treatment started 24 hours before surgery. Serum aminoglycoside pharmacokinetics were examined during treatment and renal cortical tissue was sampled at the moment of operation for drug determination. The short-term infusion schedule yielded cortical concentrations of 103.2 +/- 36.3 and 137.4 +/- 34.6 micrograms/gm for gentamicin and netilmicin, respectively. Tissue levels after continuous infusion were 158.1 +/- 52.9 and 178.5 +/- 21.8 micrograms/gm for gentamicin and netilmicin, respectively. For each aminoglycoside, a single short-term infusion resulted in significantly lower renal drug levels than did a continuous infusion of the same dose. From the nephrotoxicity point of view, these data support the administration of gentamicin and netilmicin as once-daily injections. This also supports the appropriateness of further studies to determine clinical efficacy of once-a-day dosing for aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910634     DOI: 10.1038/clpt.1989.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  51 in total

Review 1.  Antibacterial-induced nephrotoxicity in the newborn.

Authors:  V Fanos; L Cataldi
Journal:  Drug Saf       Date:  1999-03       Impact factor: 5.606

2.  Pharmacokinetics and antibacterial activity of daily gentamicin.

Authors:  H Skopnik; R Wallraf; B Nies; K Tröster; G Heimann
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

3.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

Review 4.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

5.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

6.  Effect of isepamicin dosing scheme on concentration in cochlear tissue.

Authors:  P J Govaerts; J Claes; P H Van de Heyning; M P Derde; L Kaufman; J F Marquet; M E De Broe
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

8.  Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

Authors:  P J Wood; L L Ioannides-Demos; E B Bastone; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

9.  Aminoglycoside dosages and nephrotoxicity: quantitative relationships.

Authors:  Florent Rougier; Michel Ducher; Michel Maurin; Stéphane Corvaisier; Daniel Claude; Roger Jelliffe; Pascal Maire
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics.

Authors:  F Fauvelle; P Perrin; L Belfayol; M Boukari; P Cherrier; A M Bosio; M Tod; J M Coulaud; O Petitjean
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.